Recursion Capital Expenditures vs Begin Period Cash Flow Analysis

RXRX Stock

USD 7.46 0.81 9.79%

Recursion Pharmaceuticals financial indicator trend analysis is much more than just breaking down Recursion Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Recursion Pharmaceuticals is a good investment. Please check the relationship between Recursion Pharmaceuticals Capital Expenditures and its Begin Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Capital Expenditures vs Begin Period Cash Flow

Capital Expenditures vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Recursion Pharmaceuticals Capital Expenditures account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Recursion Pharmaceuticals' Capital Expenditures and Begin Period Cash Flow is 0.63. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Recursion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Recursion Pharmaceuticals' Capital Expenditures and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Recursion Pharmaceuticals are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Capital Expenditures i.e., Recursion Pharmaceuticals' Capital Expenditures and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.63

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Recursion Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Recursion Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Recursion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Recursion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.At this time, Recursion Pharmaceuticals' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.9 B in 2024, whereas Selling General Administrative is likely to drop slightly above 64.7 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	8.4M	11.8M	24.4M	25.6M
Interest Income	73K	6.3M	18.3M	19.2M

Depreciation And Amortization Interest Income

Recursion Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.76	0.97	0.96	0.95	0.84	0.94	0.94	-0.96	-0.88	0.94	0.96	0.83	0.96	0.62	-0.98	0.98	0.78	0.73	-0.53	0.86	-0.86	0.77	0.92	-0.25	0.95
Short Long Term Debt Total	0.76		0.7	0.91	0.69	0.9	0.71	0.92	-0.8	-0.84	0.89	0.83	0.82	0.67	0.22	-0.72	0.66	0.24	0.79	-0.4	0.98	-0.76	0.77	0.77	-0.11	0.69
Other Current Liab	0.97	0.7		0.91	0.9	0.83	0.9	0.88	-0.9	-0.89	0.86	0.89	0.85	0.91	0.47	-0.94	0.93	0.77	0.8	-0.45	0.8	-0.89	0.81	0.89	-0.18	0.89
Total Current Liabilities	0.96	0.91	0.91		0.9	0.91	0.9	0.99	-0.95	-0.91	0.98	0.97	0.87	0.9	0.5	-0.93	0.91	0.6	0.79	-0.51	0.97	-0.87	0.81	0.91	-0.21	0.9
Total Stockholder Equity	0.95	0.69	0.9	0.9		0.74	0.97	0.91	-0.85	-0.82	0.94	0.85	0.78	0.99	0.7	-0.97	0.92	0.86	0.68	-0.77	0.82	-0.83	0.71	0.93	-0.54	1.0
Other Liab	0.84	0.9	0.83	0.91	0.74		0.84	0.91	-0.89	-0.97	0.88	0.88	0.97	0.74	0.18	-0.85	0.77	0.42	0.9	-0.36	0.91	-0.93	0.94	0.9	-0.09	0.74
Net Tangible Assets	0.94	0.71	0.9	0.9	0.97	0.84		0.91	-0.86	-0.91	0.92	0.85	0.9	0.96	0.54	-0.99	0.91	0.82	0.79	-0.73	0.82	-0.93	0.85	0.99	-0.51	0.97
Property Plant And Equipment Net	0.94	0.92	0.88	0.99	0.91	0.91	0.91		-0.91	-0.91	0.99	0.93	0.88	0.9	0.49	-0.92	0.87	0.6	0.81	-0.59	0.98	-0.88	0.82	0.92	-0.3	0.91
Net Debt	-0.96	-0.8	-0.9	-0.95	-0.85	-0.89	-0.86	-0.91		0.86	-0.92	-1.0	-0.81	-0.88	-0.56	0.92	-0.96	-0.62	-0.67	0.35	-0.87	0.81	-0.74	-0.86	0.05	-0.84
Retained Earnings	-0.88	-0.84	-0.89	-0.91	-0.82	-0.97	-0.91	-0.91	0.86		-0.88	-0.85	-0.99	-0.82	-0.22	0.9	-0.8	-0.56	-0.95	0.49	-0.89	0.99	-0.98	-0.96	0.24	-0.82
Accounts Payable	0.94	0.89	0.86	0.98	0.94	0.88	0.92	0.99	-0.92	-0.88		0.93	0.85	0.93	0.57	-0.94	0.89	0.64	0.75	-0.64	0.96	-0.85	0.78	0.93	-0.37	0.94
Cash	0.96	0.83	0.89	0.97	0.85	0.88	0.85	0.93	-1.0	-0.85	0.93		0.8	0.87	0.57	-0.91	0.95	0.6	0.67	-0.36	0.9	-0.8	0.73	0.84	-0.05	0.85
Non Current Assets Total	0.83	0.82	0.85	0.87	0.78	0.97	0.9	0.88	-0.81	-0.99	0.85	0.8		0.77	0.15	-0.87	0.75	0.53	0.95	-0.5	0.85	-0.99	0.99	0.95	-0.27	0.78
Non Currrent Assets Other	0.96	0.67	0.91	0.9	0.99	0.74	0.96	0.9	-0.88	-0.82	0.93	0.87	0.77		0.72	-0.98	0.96	0.88	0.66	-0.72	0.8	-0.83	0.7	0.92	-0.48	0.99
Other Assets	0.62	0.22	0.47	0.5	0.7	0.18	0.54	0.49	-0.56	-0.22	0.57	0.57	0.15	0.72		-0.6	0.71	0.74	-0.04	-0.53	0.37	-0.22	0.03	0.43	-0.4	0.7
Long Term Debt	-0.98	-0.72	-0.94	-0.93	-0.97	-0.85	-0.99	-0.92	0.92	0.9	-0.94	-0.91	-0.87	-0.98	-0.6		-0.96	-0.83	-0.76	0.65	-0.84	0.91	-0.81	-0.97	0.41	-0.97
Cash And Short Term Investments	0.98	0.66	0.93	0.91	0.92	0.77	0.91	0.87	-0.96	-0.8	0.89	0.95	0.75	0.96	0.71	-0.96		0.82	0.6	-0.49	0.78	-0.79	0.67	0.87	-0.22	0.92
Net Receivables	0.78	0.24	0.77	0.6	0.86	0.42	0.82	0.6	-0.62	-0.56	0.64	0.6	0.53	0.88	0.74	-0.83	0.82		0.42	-0.69	0.43	-0.63	0.47	0.73	-0.57	0.86
Common Stock Shares Outstanding	0.73	0.79	0.8	0.79	0.68	0.9	0.79	0.81	-0.67	-0.95	0.75	0.67	0.95	0.66	-0.04	-0.76	0.6	0.42		-0.44	0.81	-0.95	0.97	0.86	-0.23	0.68
Non Current Liabilities Total	-0.53	-0.4	-0.45	-0.51	-0.77	-0.36	-0.73	-0.59	0.35	0.49	-0.64	-0.36	-0.5	-0.72	-0.53	0.65	-0.49	-0.69	-0.44		-0.51	0.56	-0.45	-0.7	0.95	-0.77
Capital Lease Obligations	0.86	0.98	0.8	0.97	0.82	0.91	0.82	0.98	-0.87	-0.89	0.96	0.9	0.85	0.8	0.37	-0.84	0.78	0.43	0.81	-0.51		-0.83	0.8	0.86	-0.22	0.82
Inventory	-0.86	-0.76	-0.89	-0.87	-0.83	-0.93	-0.93	-0.88	0.81	0.99	-0.85	-0.8	-0.99	-0.83	-0.22	0.91	-0.79	-0.63	-0.95	0.56	-0.83		-0.98	-0.97	0.33	-0.83
Other Current Assets	0.77	0.77	0.81	0.81	0.71	0.94	0.85	0.82	-0.74	-0.98	0.78	0.73	0.99	0.7	0.03	-0.81	0.67	0.47	0.97	-0.45	0.8	-0.98		0.91	-0.24	0.71
Other Stockholder Equity	0.92	0.77	0.89	0.91	0.93	0.9	0.99	0.92	-0.86	-0.96	0.93	0.84	0.95	0.92	0.43	-0.97	0.87	0.73	0.86	-0.7	0.86	-0.97	0.91		-0.47	0.93
Total Liab	-0.25	-0.11	-0.18	-0.21	-0.54	-0.09	-0.51	-0.3	0.05	0.24	-0.37	-0.05	-0.27	-0.48	-0.4	0.41	-0.22	-0.57	-0.23	0.95	-0.22	0.33	-0.24	-0.47		-0.54
Net Invested Capital	0.95	0.69	0.89	0.9	1.0	0.74	0.97	0.91	-0.84	-0.82	0.94	0.85	0.78	0.99	0.7	-0.97	0.92	0.86	0.68	-0.77	0.82	-0.83	0.71	0.93	-0.54

Click cells to compare fundamentals

Recursion Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Recursion Capital Expenditures vs Begin Period Cash Flow Analysis

Capital Expenditures vs Begin Period Cash Flow

Capital Expenditures vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Capital Expenditures

Begin Period Cash Flow

Recursion Pharmaceuticals fundamental ratios Correlations

Recursion Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Recursion Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Net	+ 0.99	Total Current Liabilities
Non Currrent Assets Other	+ 0.99	Total Stockholder Equity
Other Stockholder Equity	+ 0.99	Net Tangible Assets
Accounts Payable	+ 0.99	Property Plant And Equipment Net
Inventory	+ 0.99	Retained Earnings

Cash	- 1.0	Net Debt
Inventory	- 0.99	Non Current Assets Total
Non Current Assets Total	- 0.99	Retained Earnings
Long Term Debt	- 0.99	Net Tangible Assets
Other Current Assets	- 0.98	Inventory
Long Term Debt	- 0.98	Non Currrent Assets Other